Oculis (OCSAW) Stock Price, News & Analysis

Company Overview

Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.

Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States. The company completed a U.S. initial public offering in 2020 and maintains laboratories in Lausanne and Boston to support formulation development and clinical operations. Oculis has forged collaborations with academic centers and contract research organizations to advance preclinical models and early‐stage clinical trials, strengthening its position in the global ophthalmology sector.

Oculis is led by Chief Executive Officer Richard Assmus and a management team with extensive experience in biotechnology and ophthalmic drug development. Co‐founder and Chief Scientific Officer Luigi Corsini oversees the scientific strategy, drawing on two decades of expertise in ocular pharmacology. Together, the leadership team aims to translate the company’s platform technologies into safe, effective therapies that can preserve and restore vision for patients worldwide.

Key Stats

• Today's Range: $4.88 to $6.82
• 50-Day Range: $5.04 to $7.83
• 52-Week Range: $1.99 to $11.50
• Volume: 4,839 shs
• Average Volume: 11,910 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OCSAW Stock Analysis - Frequently Asked Questions

How have OCSAW shares performed this year?

Oculis' stock was trading at $5.39 at the beginning of 2025. Since then, OCSAW shares have increased by 20.5% and is now trading at $6.4950.

How do I buy shares of Oculis?

Shares of OCSAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OCSAW
• CIK: 1953530
• Web: www.oculis.com
• Phone: 41-58-810-0182
• Fax: N/A
• Employees: 32
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A